Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer MAP Pharmaceuticals has received the dreaded one-star ranking.
With that in mind, let's take a closer look at MAP and see what CAPS investors are saying about the stock right now.
Mountain View, Calif. (2003)
CEO Timothy Nelson (since 2005)
Return on Capital (average, past 3 years)
$114.2 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 34% of the 96 members who have rated MAP believe the stock will underperform the S&P 500 going forward.
MAP has no revenue and is losing large amounts of money each quarter (four in a row now). Before the recent financing deal it was worth less than $14 million on paper. Even now it's worth less than $60 million, which doesn't support a $540 million market cap.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why MAP Pharmaceuticals Is Poised to Plunge originally appeared on Fool.com.
Fool contributor Brian Pacampara and The Motley Fool have no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.